Drug Trial Radar · NCT07566429
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jan 25, 2027
Primary completion
Jun 15, 2029
Study completion Dec 15, 2032
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- AskBio Inc
- First posted
- May 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).
Conditions
- Parkinson Disease
Interventions
AB-1005Drug
Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events up to Month 18 after study interventionTime frame: Up to 18 months
- Change from Baseline to Month 18 in normalized Good ON time measured with PD Motor DiaryTime frame: Up to 18 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
National Hospital Organization Utano National Hospital - Neurology
Kyoto, Japan
Nagoya Central Hospital - Neurosurgery
Nagoya, Aichi-ken, Japan
Nagoya University Hospital - Neurology
Nagoya, Aichi-ken, Japan
Yokohama City University Medical Center - Neurology
Yokohama, Kanagawa, Japan
National Hospital Organization Osaka Toneyama Medical Center - Neurology
Toyonaka, Osaka, Japan
Juntendo University Hospital - Neurology
Bunkyo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.